多剂次初免与延迟加强提高恶性疟原虫孢子体疫苗对异源攻击的保护效力
该研究在健康疟疾未暴露成人中评估不同剂量和程序的无佐剂减毒恶性疟原虫孢子体疫苗(PfSPZ Vaccine)对异源寄生虫控制人类疟疾感染(CHMI)的保护效力。结果显示多剂次初免(第1、3、5、7天各一剂,第16周加强)使40%受试者在12周异源CHMI后保持无虫血症,而单剂初免疫苗剂量递增未显著保护;对未保护者加强后24周保护率升至64%。
要点
- 多剂次初免方案(4剂堆叠)对异源CHMI的效力为40%,显著高于对照。
- 单剂初免剂量递增(9.0×10^5、18.0×10^5、27.0×10^5)未显著保护。
- 对未保护者加强后24周CHMI保护率可达64%。
核心结论
- 多剂次初免(第1、3、5、7天各一剂)使40%受试者在12周异源CHMI后保持无虫血症,而单剂初免剂量递增未显著保护。
- 对未保护者进行加强后,24周异源CHMI保护率提高至64%。
研究设计与样本
- 研究纳入4组共60名健康、疟疾未暴露成人,每组15人。
- 组1接受5剂4.5×10^5 PfSPZ(第1、3、5、7天及第16周);组2、3、4分别在第0、8、16周接受3剂,剂量分别为9.0×10^5、18.0×10^5、首剂27.0×10^5后续9.0×10^5。
- 异源CHMI在12或24周后进行;12周未保护者在24周CHMI前接受加强。
主要发现
- 12周CHMI时,组1有6/15(40%)保持无虫血症(P = .04),组2有3/15(20%),对照组0/8。
- 24周CHMI时,组3有3/13(23%)、组4有3/14(21%)保持无虫血症,对照组0/8,组2-4的疫苗效力无统计学显著性。
- 加强后,9/14(64%)受试者保持无虫血症,对照组0/8;其中组1为3/6(P = .025),组2为6/8(P = .002)。
临床怎么用
- 多剂次初免策略可提高PfSPZ疫苗对异源疟原虫的攻击保护力,但保护率仍有限。
- 对初免未保护者进行延迟加强可提升保护效力,提示加强免疫策略值得进一步研究。
局限性
- 研究样本量较小(每组15人),部分比较未达统计学显著性。
- 异源CHMI保护率总体不高,疫苗效力仍需在更大规模现场试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A live-attenuated Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria infection (CHMI) using homologous parasites (same P. falciparum strain as in the vaccine). Using a more stringent CHMI, with heterologous parasites (different P. falciparum strain), we assessed the impact of higher PfSPZ doses, a novel multi-dose prime regimen, and a delayed vaccine boost upon vaccine efficacy (VE). METHODS: We immunized 4 groups that each contained 15 healthy, malaria-naive adults. Group 1 received 5 doses of 4.5 x 105 PfSPZ (Days 1, 3, 5, and 7; Week 16). Groups 2, 3, and 4 received 3 doses (Weeks 0, 8, and 16), with Group 2 receiving 9.0 × 105/doses; Group 3 receiving 18.0 × 105/doses; and Group 4 receiving 27.0 × 105 for dose 1 and 9.0 × 105 for doses 2 and 3. VE was assessed by heterologous CHMI after 12 or 24 weeks. Volunteers not protected at 12 weeks were boosted prior to repeat CHMI at 24 weeks. RESULTS: At 12-week CHMI, 6/15 (40%) participants in Group 1 (P = .04) and 3/15 (20%) participants in Group 2 remained aparasitemic, as compared to 0/8 controls. At 24-week CHMI, 3/13 (23%) participants in Group 3 and 3/14 (21%) participants in Group 4 remained aparasitemic, versus 0/8 controls (Groups 2-4, VE not significant). Postboost, 9/14 (64%) participants versus 0/8 controls remained aparasitemic (3/6 in Group 1, P = .025; 6/8 in Group 2, P = .002). CONCLUSIONS: Administering 4 stacked priming injections (multi-dose priming) resulted in 40% VE against heterologous CHMI, while dose escalation of PfSPZ using single-dose priming was not significantly protective. Boosting unprotected subjects improved VE at 24 weeks, to 64%. CLINICAL TRIALS REGISTRATION: NCT02601716.
引用
- Lyke KE, Singer A, Berry AA, et al. Multidose Priming and Delayed Boosting Improve Plasmodium falciparum Sporozoite Vaccine Efficacy Against Heterologous P. falciparum Controlled Human Malaria Infection. Clin Infect Dis. 2021. PMID: 32920641. doi:10.1093/cid/ciaa1294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。